Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Povella Therapeutics Second Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Marci Nanis, Vice President of Investor Relations and Corporate Affairs. Thank you, Operator. Good morning, and thank you for joining the Paul Vella Therapeutics Second Quarter 2026 Financial Results and Corporate Update Call. As a reminder, our press release detailing today's announcements can be found in the investor section of our website at www.palvellatx.com. On today's call, I am joined by Wes Kaupinen, our founder and chief executive officer, Dr. Jeff Martini, our chief scientific officer, and Matt Korenberg, our chief financial officer. Before we begin, Please note that today's remarks may include forward-looking statements regarding our development programs, regulatory strategy, commercial planning, and financial outlook. These statements are based on current assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings for a full discussion of these risk factors. And now, I'll turn the call over to Wes. Thanks, Marcy. Good morning, everyone, and thank you for joining us. The second quarter marked the culmination of many years of work to pioneer and accelerate the development...